Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ACE1831 |
Synonyms | |
Therapy Description |
ACE1831 is an antibody conjugated effector cell therapy comprising an anti-CD20 antibody conjugated to gamma delta T-lymphocytes, which potentially leads to tumor cell killing (Cancer Res 2022;82(12_Suppl):Abstract nr 5573). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ACE1831 | ACE-1831|ACE 1831 | ACE1831 is an antibody conjugated effector cell therapy comprising an anti-CD20 antibody conjugated to gamma delta T-lymphocytes, which potentially leads to tumor cell killing (Cancer Res 2022;82(12_Suppl):Abstract nr 5573). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|